Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+ Industry Domains
Report
Press Release
Blogs
Industry Statistics
Add 2 More Reports For 20% off

Report Overview

Psoriatic arthritis (PsA) remains a chronic, systemic immune-mediated inflammatory musculoskeletal disease associated with psoriasis and characterized by heterogeneous involvement of peripheral joints, axial structures, entheses, digits, skin and nails. According to Kalyoncu and Ayan in a 2026 global epidemiology review, population-based studies estimate PsA prevalence at approximately 0.1–0.2% of the general population, although considerable geographic variability remains because of differences in case ascertainment and classification. According to the psoriatic arthritis epidemiology forecast by Expert Market Research, PsA continues to represent a significant clinical and healthcare burden because delayed recognition can permit irreversible structural damage, functional disability and reduced quality of life, while obesity, cardiovascular disease, depression, inflammatory bowel disease and uveitis frequently complicate treatment selection

2025

Base Year

2019-2025

Historical Period

2026-2035

Forecast Period

Psoriatic Arthritis – Number of Cases by Year

Read more about this report - Request a Free Sample

Psoriatic Arthritis Epidemiology Forecast Report Coverage

Expert Market Research's “Psoriatic Arthritis Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of Psoriatic Arthritis. It projects the future incidence and prevalence rates of Psoriatic Arthritis cases across various populations. The study covers age, gender, and type as major determinants of the Psoriatic Arthritis population. The report highlights patterns in the prevalence of Psoriatic Arthritis overtime and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of Psoriatic Arthritis in the 8 major markets.

Regions Covered

  • United States
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Japan
  • India

Psoriatic Arthritis Understanding: Disease Overview

Psoriatic arthritis (PsA) remains a chronic, systemic immune-mediated inflammatory musculoskeletal disease associated with psoriasis and characterized by heterogeneous involvement of peripheral joints, axial structures, entheses, digits, skin and nails. Unlike rheumatoid arthritis, PsA may produce both erosive bone destruction and pathological new bone formation, and individual patients can exhibit markedly different combinations of arthritis, enthesitis, dactylitis, axial disease and extra-musculoskeletal manifestations. Current understanding emphasizes interaction among innate and adaptive immune pathways, genetic susceptibility, mechanical stress, obesity, psoriasis severity and other environmental factors, with the IL-23/IL-17 axis, TNF signaling and JAK-STAT pathways playing central therapeutic roles.

Key Report Insights

Parameter

Insight

Largest Patient Pool

India

Fastest Growing Country

India

High-Risk Population

Patients with psoriasis, particularly those with nail or scalp psoriasis, obesity, arthralgia, severe skin disease, family history of PsA or uveitis,

Key Diagnostic Method

Clinical assessment by a rheumatologist, supported by CASPAR classification features and imaging,

Major Risk Factor

Pre-existing psoriasis

Major gap in the market

Delayed diagnosis, inadequate screening of psoriasis populations, heterogeneous treatment response, persistent multidomain disease, treatment-refractory PsA, incomplete prediction of progression and limited validated biomarkers

Psoriatic Arthritis Epidemiology Perspective

The Psoriatic Arthritis epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the Psoriatic Arthritis epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Psoriatic Arthritis and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

Epidemiology Segment

Key Insights

Diagnosed Prevalent Cases of the Disease

A 2024 systematic review and meta-analysis estimated worldwide PsA prevalence at 112 per 100,000 adults. Population-based studies produced a pooled estimate of 113 per 100,000, compared with 109 per 100,000 from health-administrative datasets. Prevalence was approximately 207 per 100,000 in Europe, 64 per 100,000 in North America and 37 per 100,000 in Asia.

Gender-Specific Cases of the Disease

PsA affects both sexes, and contemporary global evidence does not support a strong universal sex predominance. The 2024 psoriasis-based modelling study estimated prevalence of PsA at 19.14% in females versus 16.01% in males among people with psoriasis. More recent Italian real-world data demonstrate phenotype differences by sex rather than a simple prevalence difference: men had more axial involvement and severe skin disease, whereas women had more enthesitis and psychological comorbidity.

Age-Specific Cases of the Disease

PsA usually develops during adulthood, although it can occur at any age. The 2024 psoriasis-based modelling study estimated prevalence among adults at 23.93% of people with psoriasis, compared with 8.59% among children. Contemporary Indian data found that among a rheumatology cohort, the highest occurrence was in the 30–50-year age range, representing 53.3% of PsA cases.

Ethnicity-Wise Cases of the Disease

Psoriatic arthritis prevalence varies by ethnicity. U.S. insurance data reported PsA prevalence of 273–340 per 100,000 among White individuals, compared with 128–190 among Asian individuals, 37–190 among Black individuals, and 89–302 among Hispanic individuals, depending on insurance group. These differences may reflect variations in diagnosis, healthcare access, psoriasis prevalence, and case ascertainment.

Mortality and Survival Analysis of the Disease

PsA is not generally a rapidly fatal disease, but contemporary evidence supports modestly increased all-cause mortality compared with the general population. A 2025 systematic review and meta-analysis of 20 studies found a pooled standardized mortality ratio of 1.12 (95% CI 1.09–1.15). The excess risk was greater in Asian studies, where the pooled SMR was 1.28. Cardiovascular disease, metabolic disease and chronic systemic inflammation are important contributors to long-term risk.

Type-Specific Disease Burden and Epidemiology Analysis

Disease Type

Prevalence

Symmetric Polyarthritis

Symmetric polyarthritis affects five or more joints on both sides of the body, commonly involving the wrists, knees, and hands. This pattern resembles rheumatoid arthritis and is characterized by persistent inflammation, joint pain, swelling, and stiffness. An Indian study reported this pattern in approximately 58% of patients with psoriatic arthritis.

Asymmetric Oligoarticular Arthritis

Asymmetric oligoarticular arthritis typically affects two to four joints without corresponding involvement on both sides of the body. It commonly causes joint swelling and may involve dactylitis, resulting in sausage-like swelling of the fingers or toes. An Indian cohort reported this pattern in approximately 21% of patients, although prevalence varies across populations.

Distal Interphalangeal (DIP) Predominant

DIP-predominant psoriatic arthritis primarily affects the small joints closest to the fingernails and toenails. This pattern is frequently associated with nail abnormalities, including pitting, ridging, and discoloration, and may sometimes resemble osteoarthritis. DIP involvement was reported in approximately 3% of patients in an Indian clinical study.

Spondylitis (Axial Disease)

Spondylitis, or axial psoriatic arthritis, primarily affects the spine and sacroiliac joints. It can cause inflammatory back and neck pain, stiffness, and restricted mobility, making bending and other spinal movements difficult. An Indian study reported spondyloarthropathy in approximately 49% of patients with psoriatic arthritis, highlighting the substantial burden of axial involvement.

Arthritis Mutilans

Arthritis mutilans is the rarest and most severe form of psoriatic arthritis. It causes extensive destruction of the small bones and joints of the hands and feet, potentially resulting in significant bone loss, permanent deformity, and functional impairment. An Indian study reported this pattern in approximately 1% of patients with psoriatic arthritis.

Psoriatic Arthritis – Number of Cases by Country

Read more about this report - Request a Free Sample

Country-wise Psoriatic Arthritis Epidemiology

The psoriatic arthritis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Country

Key Insights

United States

Contemporary global meta-analysis places North America among the regions with the highest population-level PsA prevalence, estimated at 64 per 100,000 adults in population-based studies and 147 per 100,000 in health-administrative studies. Among people with psoriasis, the 2024 global modelling analysis estimated the highest regional PsA prevalence in North America at 26.59%, emphasizing the large at-risk psoriasis reservoir.

Germany

Germany has a comparatively well-developed epidemiological evidence base. A 2024 claims-based study reported PsA within the German statutory-health-insurance population, with prevalence varying according to case definition; the authors found prevalence of 0.11–0.32% for PsA across the German evidence base reviewed. Because the underlying claims observation period predates 2023, the figures are reported here only as the contemporary publication's evidence context rather than as newly collected 2023–2026 prevalence.

France

France is part of the European region in which pooled population-based PsA prevalence is substantially higher than in Asia. The 2024 global meta-analysis estimated 207 per 100,000 adults in Europe using population-based studies and 175 per 100,000 using health-administrative studies. A recent nationally representative French 2023–2026 PsA prevalence estimate was not identified in the reviewed literature, so no historical national percentage is substituted.

Italy

The 2025 multicentre MAPSI study enrolled PsA patients diagnosed or confirmed by rheumatologists across 25 Italian rheumatology units and documented meaningful sex-specific phenotype differences. Men showed more axial involvement and more severe skin disease, while women had higher enthesitis and psychological comorbidity. Inflammatory markers were elevated in only about half of patients, underscoring the limitations of laboratory testing for diagnosis.

Spain

Spain falls within the higher-prevalence European PsA region. The 2024 global population meta-analysis estimated European prevalence at 207 per 100,000 adults in population-based studies. Contemporary Spanish literature also contributes substantially to research on central sensitization, treatment refractoriness and multidisciplinary management. A sufficiently robust national 2023–2026 prevalence estimate was not identified, so older national estimates have not been inserted.

United Kingdom

The UK provides contemporary evidence from the psoriasis-to-PsA continuum. The 2024 global modelling analysis estimated PsA incidence among people with psoriasis at 2.31 per 1,000 person-years in the UK, one of the lower country-specific incidence estimates reported in that analysis. More recent English OpenSAFELY research found that cumulative PsA diagnoses remained 24.9% below predicted levels by March 2025, indicating a persistent post-pandemic diagnostic deficit.

Japan

Japan contributes to the global evidence base but remains a relatively lower-prevalence region than Europe and North America. The 2024 global meta-analysis estimated population-based PsA prevalence at 37 per 100,000 adults in Asia, compared with 207 per 100,000 in Europe. Contemporary reviews emphasize that geographic differences may partly reflect underdiagnosis and differences in ascertainment rather than a truly lower biological burden.

India

India has limited population-level contemporary surveillance, but recent clinical evidence demonstrates substantial unmet diagnostic need. A 2024 Mumbai study of psoriasis patients in rheumatology practice identified 41 PsA cases among 60 patients evaluated, with mean PsA onset at 38.88 years and the highest occurrence between 30 and 50 years. Because the cohort was a selected clinical sample, its 68.3% figure must not be extrapolated to Indian population prevalence.

Key Market Gaps, Untapped Opportunities, and Emerging Growth Areas in the Regional Disease Epidemiology Landscape

According to contemporary 2023-2026 evidence, substantial gaps remain in the epidemiological characterization, early diagnosis, risk prediction, disease monitoring and long-term management of psoriatic arthritis. The 2024 worldwide systematic review estimated global population prevalence at 112 per 100,000 adults, while the 2024 modelling study estimated that 17.58% of people with psoriasis have PsA. The large difference between general-population and psoriasis-denominator estimates demonstrates that PsA epidemiology must distinguish the general population from the much larger psoriasis reservoir. A major opportunity therefore exists in screening people with psoriasis before clinically apparent arthritis develops. Recent literature estimates that more than 80% of PsA cases are preceded by psoriasis, creating a clinically important window for surveillance.

Psoriatic Arthritis: Treatment Overview

The management of psoriatic arthritis primarily focuses on suppressing inflammation, preventing structural joint damage, controlling all clinically important disease domains, maintaining physical function, achieving remission or low disease activity, treating associated psoriasis and minimizing the effects of comorbidity. Contemporary management has moved decisively toward domain-based, treat-to-target and individualized therapy, because peripheral arthritis, axial disease, enthesitis, dactylitis, skin disease, nail disease, uveitis and inflammatory bowel disease may coexist in the same patient. The 2024 EULAR update, based on a systematic literature review and international consensus process, recommends short-term NSAID monotherapy only for mild disease and does not recommend oral glucocorticoids as routine treatment. For peripheral arthritis, rapid initiation of a conventional synthetic DMARD is recommended, with methotrexate preferred, followed by a biological DMARD when the treatment target is not achieved.

Key Questions Answered

  • What is the current and projected burden of Psoriatic Arthritis across the 8 major markets?
  • Which countries across the 8 major markets account for the highest Psoriatic Arthritis patient populations and fastest growth rates?
  • What is the diagnosed versus undiagnosed patient population of Psoriatic Arthritis across key countries in the 8 major markets?
  • Which countries demonstrate the largest gaps in screening, early diagnosis, and disease awareness of Psoriatic Arthritis across the 8 major markets?
  • What are the major drivers contributing to the increasing burden of Psoriatic Arthritis across the 8 major markets?
  • How do major comorbidities and risk factors influence Psoriatic Arthritis epidemiology trends across the 8 major markets?
  • What are the regional trends in advanced disease progression, treatment uptake, and patient management of Psoriatic Arthritis across the 8 major markets?
  • Which patient segments represent the highest unmet clinical need in the Psoriatic Arthritis landscape across the 8 major markets?
  • Which therapeutic areas linked to Psoriatic Arthritis are expected to witness the strongest growth opportunities across the 8 major markets?
  • How is the Psoriatic Arthritis epidemiology landscape expected to evolve over the next 5 to 10 years across the 8 major markets?
  • Which countries across the 8 major markets offer the most attractive market opportunities based on Psoriatic Arthritis epidemiology and healthcare infrastructure?
  • Which epidemiological trends are expected to influence future drug development and market access strategies for Psoriatic Arthritis across the 8 major markets?

Scope of the Psoriatic Arthritis Epidemiology Report

  • The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Psoriatic Arthritis based on several factors.
  • Psoriatic Arthritis Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
  • The Psoriatic Arthritis report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Rheumatoid Arthritis Therapeutics Market

Osteoarthritis Therapeutics Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Report Features

Details

Base Year

2025

Historical Period

2019-2025

Forecast Period

2026-2035

Epidemiology Statistics Provided

  • Diagnosed Prevalent Cases
  • Type-Specific Cases
  • Gender-Specific Cases
  • Age-Specific Cases

Segmentation Provided

  • Epidemiology by Age Group
  • Epidemiology by Gender
  • Epidemiology by Type of Disease
  • Epidemiology by Region

Geographies Covered

  • United States
  • Germany
  • Italy
  • France
  • Spain
  • United Kingdom
  • Japan
  • India

Datasheet

10 % Off

USD

2,699

2,429

Single User License

10 % Off

USD

4,299

3,869

Five User License

15 % Off

USD

5,799

4,949

Corporate License

15 % Off

USD

6,999

5,949

Datasheet

One User

USD 2,699

USD 2,429

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 4,299

USD 3,869

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 5,799

USD 4,949

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 6,999

USD 5,949

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complimentary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

This is a collaborative report by Vishakha Agrawal reflecting perspectives and research-driven insights from Expert Market Research.

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

License Type

Select License Type

Choose the right license for your needs and access rights.

shopping cart

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Bookmark Icon

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us